

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

## NRx Pharmaceuticals, Inc. (NRXP) – Buy

August 15, 2023

### NRx Reports the Quarter

**Jason H. Kolbert**  
 Managing Director & Senior Analyst  
 jkolbert@dawsonjames.com

NRx Pharma reports second quarter with a net loss of \$8.7M, closing the period with \$15M in cash and equivalents. Management stated: “These working capital assets are expected to fund the Company’s operations through the fourth quarter of this year, which is when we expect data from our ongoing Phase 2b/3 trial”. In June the Company announced it had entered a strategic partnership with Lotus Pharmaceuticals (not rated) and Alvogen Pharmaceuticals (not rated) to further work towards the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression for global markets. NRx is entitled to receive \$10 million upon a successful Phase 2b/3 data readout and completion of an FDA Type B meeting. NRx is eligible to receive payment of \$5 million upon receipt of FDA approval for NRX-101 as well as bonus milestone payments of up to \$315 million based on reaching certain net sales targets.


#### Investment Highlights (Press Release):

**NRX-101 Remains the Key Driver:** What is it? It is a fixed dose combination of D-cycloserine and lurasidone. It has been granted Fast Track Designation, Breakthrough Therapy Designation, It has a Special Protocol Agreement, and a Biomarker Letter of Support from the FDA for Severe Bipolar Depression with Acute Suicidal Ideation. In June, the Company announced an agreement with Alvogen Pharmaceuticals and Lotus Pharmaceuticals to fund the late-stage clinical trials of NRX-101 and to bring it to a global patient population with suicidality. Upon payment of the first \$10 million milestone, triggered by positive clinical data from the ongoing trial and FDA comments, Alvogen will be responsible for all development, regulatory and commercial costs of NRX-101 in this indication.

**NRX-101 for Pain:** In June 2023, the Company announced a prioritization of chronic pain as the next focus on NRX-101’s development. DCS has been shown to modulate the Pain Pathway at each point in the chain: pain transmission at dorsal horn of the spinal cord, pain perception in the thalamus (“paleo brain”), and pain memory and processing between the paleo brain and the cortex.

**Valuation:** We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We do assume additional capital raises. We also assume the company repurchases stock in its outyears, (or we may even see a license deal that brings in non-dilutive capital and reduces our assumed development expenses. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of \$9.0.

**Risks to our thesis include:** 1. Regulatory Approvals; 2. Clinical Science 3. Intellectual Capital 4. Dilution.



Source: NRx Pharmaceuticals

Stock Data			
52-Week Range	\$0.30	-	\$1.54
Shares Outstanding (mil.)	70.3		
Market Capitalization (mil.)	\$23		
Enterprise Value (mil.)	\$8		
Debt to Capital	0%		
Book Value/Share	\$7.69		
Price/Book	10.0		
Average Three Months Trading Volume (K)	61		
Insider Ownership	39.9%		
Institutional Ownership	14.1%		
Short interest (mil.)	1.5%		
Dividend / Yield	\$0.00/0.0%		



**Valuation:** Our valuation for NRx Pharmaceuticals is based on revenue projections out to 2033. We know the markets are quite large for depression, PTSD, and related disorders. Success in one area leads to other indications. Our model assumes the company does raise additional capital. However, we also assume that with success, the company can repurchase stock (in the out-years) and create an efficient capital structure, and we may see an early license deal that brings in non-dilutive capital and or reduces expenses. This change is what principally drives our valuation target from \$3.0 (which was based on a fully diluted share count in 2033) to \$9.0. In our model, we assume a rising SG&A and R&D as the company commercializes its products and expands its pipeline, coupled with an improving cost of goods sold (COGS) initially at 20% and at scale falling to just 10%. Our valuation models: Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP), use a 30% discount rate. We select 30% for micro-capitalized growth companies, and this represents our highest risk rate. The result of these three models is then equal-weighted and averaged, and rounded to the nearest whole number to provide a 12-month target price.

### Exhibit 1. Free Cash Flow Model

Average	\$	9
Price Target	\$	7
Year		2023

#### DCF Valuation Using FCF (mil):

Units ('000)	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
EBIT	(39,816)	(48,076)	(27,920)	(28,199)	9,519	211,234	380,946	565,656	837,362	1,030,866	1,150,374	1,328,536
Tax Rate	0%	0%	0%	0%	5%	8%	10%	18%	24%	28%	30%	31%
EBIT(1-t)	(39,816)	(48,076)	(27,920)	(28,199)	9,043	194,335	342,852	463,838	636,395	742,223	805,262	916,690
CapEx												
Depreciation												
Change in NWC												
FCF	(39,816)	(48,076)	(27,920)	(28,199)	9,043	194,335	342,852	463,838	636,395	742,223	805,262	916,690
PV of FCF	(51,761)	(48,076)	(21,477)	(16,686)	4,116	68,042	92,340	96,096	101,420	90,989	75,936	66,495
Discount Rate												
Long Term Growth Rate												
Terminal Cash Flow												
Terminal Value YE2033												
NPV												
NPV-Debt												
Shares out (thousands)												
NPV Per Share												

Source: Dawson James estimates

### Exhibit 2. Discounted EPS Model

Current Year	2023
Year of EPS	2033
Earnings Multiple	15
Discount Factor	30%
Selected Year EPS	\$ 9.15
NPV	\$ 9.96

Source: Dawson James estimates

		Discount Rate and Earnings Multiple Varies, Year is Constant					
		2033 EPS					
Earnings Multiple	10.0	5%	10%	15%	20%	25%	30%
	5		\$28.10	\$17.64	\$11.31	\$7.39	\$4.91
10		\$56.19	\$35.29	\$22.62	\$14.78	\$9.83	\$ 6.64
15		\$84.29	\$52.93	\$33.94	\$22.17	\$14.74	\$ 9.96
20		\$112.38	\$70.58	\$45.25	\$29.56	\$19.66	\$ 13.28
25		\$140.48	\$88.22	\$56.56	\$36.96	\$24.57	\$ 16.60
30		\$168.57	\$105.87	\$67.87	\$44.35	\$29.48	\$ 19.92
35		\$196.67	\$123.51	\$79.19	\$51.74	\$34.40	\$ 23.24
40		\$224.76	\$141.15	\$90.50	\$59.13	\$39.31	\$ 26.56

### Exhibit 3. Sum-of-the-Parts Model

NRx Pharmaceuticals	LT Gr	Discount Rate	Yrs. to Mkt Peak	% Success	Peak Sales MM's	Term Val
NRX-101 for BPD	1%	30%	5	80%	\$800	\$2,759
NPV						\$4.75
NRX-101 for PTSD	1%	30%	5	80%	\$800	\$2,759
NPV						\$4.75
NPV						
						80%
MM Shrs OS (2030E)						100
Total						\$9.50

Source: Dawson James estimates

**Risks to our thesis include** 1. Regulatory Approvals; 2. Clinical Science; 3. Intellectual Capital 4. Dilution

- **Regulatory Approvals.** The company's products require regulatory approvals, and there can be no assurances that the requirements to achieve these approvals can be met. Furthermore, even if a drug product is approved, the regulators may impose limitations on the use or marketing of such product.
- **Clinical Science:** The company will need to demonstrate to its "sophisticated" clients (doctors and other physicians) that the product is effective, reliable, accessible, and marketable.
- **The Competitive Landscape & IP.** The company does have intellectual properties and knows how to protect the utility of its drugs; however, our patent position is highly uncertain.
- **Dilution:** The company is likely to incur losses for the foreseeable future until it is able to generate sufficient revenue from product sales. Our model assumes a rising share count. There can be no assurances that the company can successfully raise the capital required to execute its business strategy.

**Exhibit 4. Income Statement**


NRx Pharmaceuticals: Income Statement																
000 : YE December 31	2022A	1Q23A	2Q23A	3Q23E	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
<b>Product sales</b>	-	-	-	-	-	-	-	-	50,000	200,000	300,000	400,000	600,000	660,000	726,000	798,600
NRX-101 for BPD	-	-	-	-	-	-	-	-	-	100,000	200,000	300,000	420,000	588,000	646,800	711,480
NRX-101 for PTSD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Product Sales</b>	-	-	-	-	-	-	-	-	50,000	300,000	500,000	700,000	1,020,000	1,248,000	1,372,800	1,510,080
<b>Expenses</b>																
COGS	-	-	-	-	-	-	-	-	12,000	60,000	90,000	105,000	153,000	187,200	192,192	151,008
COGS %	0%	0%	0%	0%	0%	0%	0%	0%	24%	20%	18%	15%	15%	15%	14%	10%
Research and Development	17,027	3,650	3,873	5,108	7,801	20,432	24,519	29,423	23,538	18,830	19,019	20,921	25,105	30,126	30,427	30,731
General and Administrative	27,370	5,785	4,065	6,911	10,883	27,644	27,920	28,199	28,481	28,766	29,054	29,344	29,638	29,934	30,234	30,536
Settlement Expense	-	-	250	-	-	-	-	-	-	-	-	-	-	-	-	-
Reimbursement of expenses from Relief Therapeutics	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Operating Expenses</b>	44,397	9,435	8,188	12,019	18,684	48,076	27,920	28,199	40,481	88,766	119,054	134,344	182,638	217,134	222,426	181,544
Loss from Operations	(44,397)	(9,435)	(8,188)	(12,019)	(18,684)	(48,076)	(27,920)	(28,199)	9,519	211,234	380,946	565,656	837,362	1,030,866	1,150,374	1,328,536
<b>Other (income) Expenses</b>																
Gain on extinguishment of debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income	(249)	(156)	(145)	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense - Convertible note	505	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability	(255)	1,772	663	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of Earnout Cash liability	(4,582)	(12)	11	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total other (income) expense</b>	(4,581)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Net Loss</b>	(39,816)	(11,039)	(8,717)	(12,019)	(18,684)	(48,076)	(27,920)	(28,199)	9,519	211,234	380,946	565,656	837,362	1,030,866	1,150,374	1,328,536
Tax Rate	0%	0%	0%	0%	0%	0%	0%	0%	5%	8%	10%	18%	24%	28%	30%	31%
<b>GAAP Net Income (loss)</b>	(39,816)	(10,933)	(8,845)	(12,019)	(18,684)	(48,098)	(27,920)	(28,199)	9,043	194,335	342,852	463,838	636,395	742,223	805,262	916,690
<b>GAAP-EPS</b>	(0.61)	(0.16)	(0.12)	(0.11)	(0.14)	(0.54)	(0.19)	(0.15)	0.04	0.90	1.59	2.14	2.93	3.40	3.68	9.15
GAAP EPS (dil)	(0.61)	(0.13)	(0.09)	(0.10)	(0.12)	(0.42)	(0.16)	(0.12)	0.03	0.74	1.30	1.75	2.39	3.40	3.68	9.15
Wgtd Avg Shrs (Bas) '000	65,767	67,454	73,221	109,313	130,406	95,099	150,062	194,209	213,881	214,738	215,598	216,462	217,329	218,200	219,074	100,150
Wgtd Avg Shrs (Dil) '000	65,767	82,897	103,726	124,763	151,011	115,599	176,225	234,097	261,975	263,024	264,078	265,136	266,198	267,264	268,335	100,150

Source: Dawson James estimates, company reports

Companies mentioned in this report:

**Important Disclosures:**

**Price Chart:**



Price target and ratings changes over the past three years:

- Initiated – Buy – March 17, 2023 – Price Target \$3.0
- Update Report – March 27, 2023 – Price Target \$3.0
- Update Report – March 31, 2023 – Price Target \$3.0
- Price Target Change- April 3, 2023 Price Target goes from \$3.0 to \$9.0
- Update Report – April 5, 2023 – Price Target \$9.0
- Update Report – May 17, 2023 – Price Target \$9.0
- Update Report – June 5, 2023 – Price Target \$9.0
- Update Report – August 7, 2023 – Price Target \$9.0
- Update Report – August 15, 2023 – Price Target \$9.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of August 3, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

**Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.**

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 3-Aug-23

	<b>Company Coverage</b>		<b>Investment Banking</b>	
<b>Ratings Distribution</b>	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	24	69%	3	8.60%
Market Perform (Neutral)	11	31%	3	8.60%
Market Underperform (Sell)	0	0%	0	0.00%
<b>Total</b>	<b>35</b>	<b>100%</b>	<b>6</b>	<b>17.20%</b>

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.